1mtb
From Proteopedia
| Line 1: | Line 1: | ||
| - | [[Image:1mtb.gif|left|200px]] | + | [[Image:1mtb.gif|left|200px]] |
| - | + | ||
| - | '''Viability of a drug-resistant HIV-1 protease mutant: structural insights for better antiviral therapy''' | + | {{Structure |
| + | |PDB= 1mtb |SIZE=350|CAPTION= <scene name='initialview01'>1mtb</scene>, resolution 2.50Å | ||
| + | |SITE= | ||
| + | |LIGAND= <scene name='pdbligand=QNC:2-CARBONYLQUINOLINE'>QNC</scene> and <scene name='pdbligand=DIQ:2-METHYL-DECAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID'>DIQ</scene> | ||
| + | |ACTIVITY= [http://en.wikipedia.org/wiki/HIV-1_retropepsin HIV-1 retropepsin], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.23.16 3.4.23.16] | ||
| + | |GENE= | ||
| + | }} | ||
| + | |||
| + | '''Viability of a drug-resistant HIV-1 protease mutant: structural insights for better antiviral therapy''' | ||
| + | |||
==Overview== | ==Overview== | ||
| Line 7: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
| - | 1MTB is a [ | + | 1MTB is a [[Single protein]] structure of sequence from [http://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1MTB OCA]. |
==Reference== | ==Reference== | ||
| - | Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy., Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA, J Virol. 2003 Jan;77(2):1306-15. PMID:[http:// | + | Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy., Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA, J Virol. 2003 Jan;77(2):1306-15. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12502847 12502847] |
[[Category: HIV-1 retropepsin]] | [[Category: HIV-1 retropepsin]] | ||
[[Category: Human immunodeficiency virus 1]] | [[Category: Human immunodeficiency virus 1]] | ||
| Line 25: | Line 34: | ||
[[Category: substrate recognition]] | [[Category: substrate recognition]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Mar 20 12:47:55 2008'' |
Revision as of 10:47, 20 March 2008
| |||||||
| , resolution 2.50Å | |||||||
|---|---|---|---|---|---|---|---|
| Ligands: | and | ||||||
| Activity: | HIV-1 retropepsin, with EC number 3.4.23.16 | ||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||
Viability of a drug-resistant HIV-1 protease mutant: structural insights for better antiviral therapy
Overview
Under the selective pressure of protease inhibitor therapy, patients infected with human immunodeficiency virus (HIV) often develop drug-resistant HIV strains. One of the first drug-resistant mutations to arise in the protease, particularly in patients receiving indinavir or ritonavir treatment, is V82A, which compromises the binding of these and other inhibitors but allows the virus to remain viable. To probe this drug resistance, we solved the crystal structures of three natural substrates and two commercial drugs in complex with an inactive drug-resistant mutant (D25N/V82A) HIV-1 protease. Through structural analysis and comparison of the protein-ligand interactions, we found that Val82 interacts more closely with the drugs than with the natural substrate peptides. The V82A mutation compromises these interactions with the drugs while not greatly affecting the substrate interactions, which is consistent with previously published kinetic data. Coupled with our earlier observations, these findings suggest that future inhibitor design may reduce the probability of the appearance of drug-resistant mutations by targeting residues that are essential for substrate recognition.
About this Structure
1MTB is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.
Reference
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy., Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA, J Virol. 2003 Jan;77(2):1306-15. PMID:12502847
Page seeded by OCA on Thu Mar 20 12:47:55 2008
